Survival analysis of stage IV metastatic gastric cancer patients treated with HangAm-Plus

Chinese Journal of Integrative Medicine

Volumn 20, Issue 1, 2014, Pages 49-55

  Park, Jae Woo ^a   Yoon, Jeungwon ^a   Cho, Chong Kwan ^a   Lee, Yeon Weol ^a   Yoo, Hwa Seung ^a  

^a Daejeon University   (South Korea)

Author keywords

advanced gastric cancer; Chinese materia medica; Oriental medicine; supportive care

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CHINESE DRUG; CISPLATIN; DOCETAXEL; FLUOROURACIL; HANGAM PLUS; PACLITAXEL; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BOSWELLIA SACRA; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMMIPHORA; CONTROLLED STUDY; CORDYCEPS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GINSENG; HUMAN; MALE; METASTASIS; MIDDLE AGED; NAUSEA; NEUTROPENIA; ORIENTAL MEDICINE; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84891833821     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-012-1084-0     Document Type: Article

References (37)

1. Shin HR, Won YJ, Jung KW, Park JG. 2001 annual report of the Korea Central Cancer Registry: base on registered data from 134 hospitals. Cancer Res Treat 2004;36:19-30.
2. Cancer Facts and Figures 2010. Seoul, Korea: National Cancer Center, Ministry of Health & Welfare: 2010.
3. Goekkurt E, Al-Batran SE, Mogck U, Pauligk C, Hartmann JT, Kramer M, et al. Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and doceetaxel (FLOT), a translational study of the Arbetisgemeinschaft Internistische Onkologie (AIO). Ann Oncol 2009;20:481-485.
4. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89:2207-2212
5. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591.
6. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
7. Hijioka S, Chin K, Seto Y, Yamamoto N, Hatake K. Eightyear survival after advanced gastric cancer treated with S-1 followed by surgery. World J Gastroenterol 2010;16:2824-2827.
8. Tham CK, Choo SP, Poon DY, Toh HC, Ong SY, Tan SH, et al. Capecitabine with radiation is an effective adjuvant therapy in gastric cancers. World J Gastroenterol 2010;16:3709-3715.
9. Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Earle CC, Kulke MH, et al. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Ann Oncol 2009;20:475-480.
10. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813-3818.
11. Narahara H, Koizumi W, Hara T, Takagane A, Akiya T, Takagi M, et al. TS-1 Advanced Gastric Cancer (AGC) Clinical Trial Group. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215-221.
12. Takiuchi H, Goto M, Imamura H, Furukawa H, Imano M, Imamoto H, et al. Multi-center phase II study for combination therapy with paclitaxel/ doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302). Jpn J Clin Oncol 2008;38:176-181.
13. Koizumi W, Akiya T, Sato A, Yamaguchi K, Sakuyama T, Nakayama N, et al. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the Gastrointestinal Oncology Group of the Tokyo Cooperative Oncology Group, TCOG GC-0501 Trial. Jpn J Clin Oncol 2009;39:713-719.
14. Yildiz R, Kalender ME, Dane F, Sevinc A, Gumus M, Camci C, et al. Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum and fluoropyrimidine-based regimens. J Oncol Pharm Pract 2010;16:173-178.
15. Morita S, Baba H, Tsuburaya A, Takiuchi H, Matsui T, Maehara Y, et al. A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: trial for advanced stromach cancer (TASC). Jpn J Clin Oncol 2007;37:469-472.
16. Yoo HS, Lee YY, Song KC, Choi BL, Seo SH, Cho JH, et al. The effects of HangAmDan (HAD) on anti-metastasis and preventing relapses, administered to 69 cancer patients. Kor J Orient Int Med 2002;23:165-173.
17. Park JS, Yoo HS, Lee YW, Cho JH, Son CG, Cho CK. Wheel balance cancer therapy in the treatment of metastatic gastric carcinoma: a retrospective analysis of 62 patients. Kor J Orient Int Med 2007;28:531-543.
18. Choi BL, Kim HC, Song KC, Yoo HS, Cho JH, Lee YW, et al. Study on the toxicity of HangAm-Dan (HAD) in mice. J Kor Orient Oncol 2002;8:23-35.
19. Lee DE, Lee SY, Kim JS, Cho CK, Yoo HS, Choi SJ. Antitumor effect of Hang-Am-Dan (HAD) and its ingredients on Calu6 and MCF-7 human cancer cell lines. J Kor Oriental Med 2009;30:50-60.
20. Bang JY, Kim EY, Shim TK, Yoo HS, Lee YW, Kim YS, et al. Analysis of anti-angiogenic mechanism of HangAmDan-B (HAD-B), a Korean traditional medicine, using antibody microarray chip. Bio Chip J 2010;4:350-355.
21. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. Aug 9, 2006. Retrieved from: URL: http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf
22. Korea Central Cancer Registry, Ministry of Health and Welfare. 2009. Retrieved from: URL: http://www.cancer.go.kr/cms/statics/incidence/index.html
23. Yun J, Lee J, Park SH, Park JO, Park YS, Lim HY, et al. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. Eur J Cancer 2010;46:885-891.
24. Wagner AD, Grothe W, Haerting J, Kleber G. Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-2909.
25. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009;10:1063-1069.
26. Tanabe K, Suzuki T, Tokumoto N, Yamamoto H, Yoshida K, Ohdan H. Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis. World J Surg Oncol 2010;8(40):1-7.
27. Kang YK, Ryu MH, Yoo C, Chang HM, Yook JH, Oh ST, et al. Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 2011;67:1435-1443
28. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666-673.
29. Masashi F. Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study). Int J Clin Oncol 2008;13:201-205.
30. Cunningham D, Straling N, Rao S, Iverson T, Nicloson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
31. Okines AF, Norman AR, McCloud P, Kang YK, Cunningham D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009;20:1529-1534.
32. van Cutsem E, Moiseysnko VM, Tjulandin S, Majlis A, Constenal M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-4997.
33. Keam B, Im SA, Han SW, Ham HS, Kim MA, Oh DY, et al. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer 2008;8:148-157.
34. Kim BG, Oh SY, Kwon HC, Lee s, Lee DM, Kim SG, et al. A phase II study of irinotecan with biweekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (Modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer. Am J Clin Oncol 2010;33:246-250.
35. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
36. Zhuang SH, Xiu L, Elsayed YA. Overall survival: a gold standard in search of a surrogate: the value of progressionfree survival and time to progression as end points of drug efficacy. Cancer J 2009;15:395-400.
37. Park JS, Lee YW, Cho JH, Son CG, Cho CK, Yoo HS. A case regression of advanced gastric cancer by herbal medicine a retrospective case study with 8-year follow-up. Kor J Orient Int Med 2007;28:193-198.